{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:03:54Z","timestamp":1789812234515,"version":"4.0.1"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Low-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for the development of atherosclerotic cardiovascular disease. Statins have been the gold standard for managing cholesterol levels and reducing the risks associated with atherosclerotic cardiovascular disease; however, many patients do not achieve their cholesterol goals or are unable to tolerate this drug class due to adverse drug events. Recent studies of non-statin cholesterol lowering drugs (i.e., ezetimibe, PCSK9 inhibitors) have demonstrated cardiovascular benefits; and new drugs [i.e., bempedoic acid (BDA), inclisiran] have produced promising results in pre-clinical and clinical outcome trials. This narrative review aims to discuss the place in therapy of ezetimibe, PCSK9 inhibitors, BDA, and inclisiran and describe their relative pharmacokinetic (PK) profiles, efficacy and safety as monotherapy and combination therapy, and cardiovascular benefit(s) when used for hypercholesterolemia.<\/jats:p>","DOI":"10.3389\/fcvm.2021.789931","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T06:51:44Z","timestamp":1637131904000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":65,"title":["Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol"],"prefix":"10.3389","volume":"8","author":[{"given":"Chandni","family":"Bardolia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishita Shah","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Turgeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1161\/CIRCRESAHA.118.312782","article-title":"Watts, GF, Eckel, RH. Statin toxicity mechanistic insights and clinical implications","volume":"124","year":"2019","journal-title":"Circ Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/jamacardio.2017.2289","article-title":"Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease","volume":"2","author":"Cannon","year":"2017","journal-title":"JAMA Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1080\/17512433.2019.1659133","article-title":"Statins and the potential for higher diabetes mellitus risk","volume":"12","author":"Yandrapalli","year":"2019","journal-title":"Expert Rev Clin Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.15277\/bjd.2018.180","article-title":"Cardiovascular outcomes trials with non-statin lipid-lowering drugs in diabetes","volume":"18","author":"Naeem","year":"2018","journal-title":"Brit J Diabet."},{"key":"B5","volume-title":"StatPearls","author":"Habibe","year":"2021"},{"key":"B6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","article-title":"2016 ACC expert consensus decision pathway on the role of non-statin therapies for ldl-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American college of cardiology task force on clinical expert consensus documents","volume":"68","author":"Lloyd-Jones","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rossebo","year":"2008","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jacc.2018.10.039","article-title":"Alirocumab reduces total nonfatal cardiovascular and fatal events: the Odyssey outcomes trial","volume":"73","author":"Szarek","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/jamacardio.2019.0886","article-title":"Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: a prespecified analysis from the FOURIER trial","volume":"4","author":"Murphy","year":"2019","journal-title":"JAMA Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2165\/00003088-200544050-00002","article-title":"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions","volume":"44","author":"Kosoglou","year":"2005","journal-title":"Clin Pharmacokinet."},{"key":"B16","first-page":"13a","article-title":"The pharmacokinetics of ezetimibe","volume":"10","author":"Simard","year":"2003","journal-title":"Can J Clin Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1038\/sj.bjp.0703235","article-title":"Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663","volume":"129","author":"van Heek","year":"2000","journal-title":"Br J Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/s0195-668x(02)00807-2","article-title":"Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia","volume":"24","author":"Knopp","year":"2003","journal-title":"Eur Heart J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/j.1365-2796.2008.02062.x","article-title":"Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials","volume":"265","author":"Pandor","year":"2009","journal-title":"J Intern Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/s0195-668x(02)00803-5","article-title":"Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"24","author":"Melani","year":"2003","journal-title":"Eur Heart J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/s0002-9149(02)03236-8","article-title":"Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia","volume":"91","author":"Kerzner","year":"2003","journal-title":"Am J Cardiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1161\/01.Cir.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/s0735-1097(02)02610-4","article-title":"Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia","volume":"40","author":"Davidson","year":"2002","journal-title":"J Am Coll Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.5551\/jat.35626","article-title":"Efficacy and safety of long-term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study","volume":"24","author":"Oikawa","year":"2017","journal-title":"J Atheroscler Thromb."},{"key":"B25","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.1046\/j.1523-1755.63.s84.4.x","article-title":"Study of heart and renal protection (SHARP)","volume":"84","author":"Baigent","year":"2003","journal-title":"Kidney Int Suppl."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1161\/circulationaha.117.029095","article-title":"Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (improved reduction of outcomes: vytorin efficacy international trial)","volume":"136","author":"Bohula","year":"2017","journal-title":"Circulation."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1161\/circulationaha.117.030950","article-title":"Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (improved reduction of outcomes: vytorin efficacy international trial)","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation."},{"key":"B29","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jacc.2016.11.070","article-title":"Atherothrombotic risk stratification and ezetimibe for secondary prevention","volume":"69","author":"Bohula","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e25114","DOI":"10.1097\/md.0000000000025114","article-title":"Statin\/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation","volume":"100","author":"Oh","year":"2021","journal-title":"Medicine (Baltimore)."},{"key":"B31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12944-020-01297-5","article-title":"Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression","volume":"19","author":"Masson","year":"2020","journal-title":"Lipids Health Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1056\/NEJMsa0806603","article-title":"Analyses of cancer data from three ezetimibe trials","volume":"359","author":"Peto","year":"2008","journal-title":"N Engl J Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1592\/phco.23.14.1463.31942","article-title":"Ezetimibe: a selective cholesterol absorption inhibitor","volume":"23","author":"Nutescu","year":"2003","journal-title":"Pharmacotherapy."},{"key":"B34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1146\/annurev-med-042716-091351","article-title":"PCSK9 inhibitors: mechanisms of action, metabolic effects, and clinical outcomes","volume":"69","author":"Hess","year":"2018","journal-title":"Annu Rev Med."},{"key":"B35","year":"2016","journal-title":"Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1016\/j.clinthera.2015.09.004","article-title":"Non-statin treatments for managing LDL cholesterol and their outcomes","volume":"37","author":"Turner","year":"2015","journal-title":"Clin Ther"},{"key":"B37","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40256-016-0166-3","article-title":"Alirocumab: a review in hypercholesterolemia","volume":"16","author":"Greig","year":"2016","journal-title":"Am J Cardiovasc Drugs"},{"key":"B38","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","article-title":"Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor","volume":"57","author":"Kasichayanula","year":"2018","journal-title":"Clin Pharmacokinet."},{"key":"B39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"Int J Cardiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N Engl J Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/jaha.116.003323","article-title":"Relationship between low-density lipoprotein cholesterol, free proprotein convertase subtilisin\/kexin type 9, and alirocumab levels after different lipid-lowering strategies","volume":"5","author":"Rey","year":"2016","journal-title":"J Am Heart Assoc."},{"key":"B42","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.atherosclerosis.2016.08.043","article-title":"A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I","volume":"254","author":"Roth","year":"2016","journal-title":"Atherosclerosis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.atherosclerosis.2018.07.010","article-title":"Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: pooled analysis of eight ODYSSEY phase 3 trials","volume":"277","author":"Kereiakes","year":"2018","journal-title":"Atherosclerosis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.atherosclerosis.2019.07.008","article-title":"Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: pooled analysis of nine ODYSSEY trials of alirocumab versus control","volume":"288","author":"Vallejo-Vaz","year":"2019","journal-title":"Atherosclerosis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/circulationaha.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation."},{"key":"B51","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamacardio.2020.3151","article-title":"Efficacy and safety of PCSK9 inhibition with evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving statin therapy: secondary Analysis from the FOURIER randomized clinical trial","volume":"6","author":"Deedwania","year":"2020","journal-title":"JAMA Cardiology."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1253\/circj.CJ-19-0412","article-title":"Effect of Alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndrome - the ODYSSEY J-IVUS trial","volume":"83","author":"Ako","year":"2019","journal-title":"Circ J."},{"key":"B53","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/ehjcvp\/pvz022","article-title":"PCSK9 and inflammation: a review of experimental and clinical evidence","volume":"5","author":"Momtazi-Borojeni","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"B54","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"Jama."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1093\/eurheartj\/ehw292","article-title":"No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies","volume":"37","author":"Colhoun","year":"2016","journal-title":"Eur Heart J."},{"key":"B58","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1001\/jamacardio.2018.2258","article-title":"Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis","volume":"3","author":"Sabatine","year":"2018","journal-title":"JAMA Cardiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1194\/jlr.M700437-JLR200","article-title":"Atorvastatin increases human serum levels of proprotein convertase subtilisin\/kexin type 9","volume":"49","author":"Careskey","year":"2008","journal-title":"J Lipid Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11883-016-0611-4","article-title":"Bempedoic Acid (ETC-1002): an investigational inhibitor of ATP citrate lyase","volume":"18","author":"Bilen","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1060028020941083","DOI":"10.1177\/1060028020941083","article-title":"A review of bempedoic acid: a new drug for an old problem","volume":"55","author":"Nguyen","year":"2020","journal-title":"Ann Pharmacother"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"Jama."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e011662","DOI":"10.1161\/jaha.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc."},{"key":"B66","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis."},{"key":"B67","doi-asserted-by":"publisher","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun."},{"key":"B68","first-page":"53","volume":"62","year":"2020","journal-title":"Med Lett Drugs Ther"},{"key":"B69","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","article-title":"Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies","volume":"95","author":"Wright","year":"2020","journal-title":"Mayo Clin Proc."},{"key":"B72","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N Engl J Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/cvr\/cvaa077","article-title":"Effect of inclisiran, the siRNA against PCSK9, on platelets, immune cells and immunological biomarkers - a pre-specified analysis from ORION-1","volume":"117","author":"Landmesser","year":"2020","journal-title":"Cardiovasc Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jacl.2019.11.001","article-title":"Inclisiran-new hope in the management of lipid disorders?","volume":"14","author":"Dyrbu\u015b","year":"2020","journal-title":"J Clin Lipidol."},{"key":"B76","unstructured":"Novartis Receives Complete Response Letter from U.S. FDA for Inclisiran2020"},{"key":"B77","unstructured":"Ezetimibe (Zetia\u2122)2003"},{"key":"B78","unstructured":"Regeneron and Sanofi Offer Praluent\u00ae (alirocumab) at a New Reduced U.S. List Price2019"},{"key":"B79","unstructured":"Amgen Announces 60% Reduction in List Price of PCSK9 Inhibitor Evolocumab2018"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-6-5","article-title":"Bempedoic acid for the treatment of dyslipidemia","volume":"9","author":"Marrs","year":"2020","journal-title":"Drugs Context"},{"key":"B81","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/0129784-200808060-00005","article-title":"Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model","volume":"8","author":"Ara","year":"2008","journal-title":"Am J Cardiovasc Drugs."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1001\/jamacardio.2017.3655","article-title":"Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER trial","volume":"2","author":"Arrieta","year":"2017","journal-title":"JAMA Cardiol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.mayocp.2018.08.011","article-title":"How low to go with lipid-lowering therapies in a cost-effective and prudent manner","volume":"94","author":"Cardoso","year":"2019","journal-title":"Mayo Clin Proc."},{"key":"B84","doi-asserted-by":"publisher","first-page":"221","DOI":"10.7326\/m18-1776","article-title":"Cost-effectiveness of alirocumab: a just-in-time analysis based on the ODYSSEY outcomes trial","volume":"170","author":"Kazi","year":"2019","journal-title":"Ann Intern Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease","volume":"316","author":"Kazi","year":"2016","journal-title":"Jama."},{"key":"B86","unstructured":"Esperion Confirms NEXLETOL\u2122 (Bempedoic Acid) Tablets to be Included in Assessment of Non-Statin Medicines for Hypercholesterolemia by ICER2020"},{"key":"B87","doi-asserted-by":"publisher","first-page":"961","DOI":"10.18553\/jmcp.2021.27.7.961","article-title":"The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD","volume":"27","author":"Agboola","year":"2021","journal-title":"J Manag Care Spec Pharm."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.789931\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T06:51:58Z","timestamp":1637131918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.789931\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":87,"alternative-id":["10.3389\/fcvm.2021.789931"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.789931","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,17]]},"article-number":"789931"}}